IMUX
IMMUNIC, INC.
NASDAQ · Healthcare · Biotechnology · US
$6.99
+0.29%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$6.97
From 52W high−58.64%
Volume319698.00
Market cap$95.37M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataOct 19, 2026
Open
$6.97
From 52W high
−58.64%
Volume
319698.00
Market cap
$95.37M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
0.5x
P/E (TTM)
—
RSI (14)
29.3
MomentumView details →
1D Return
+0.29%
YTD Return
+31.55%
SummaryUpdated Jun 1, 2026
Immunic, Inc. (NASDAQ:IMUX) is a clinical-stage biopharmaceutical company founded in 2016 and headquartered in New York, New York. The company went public in April 2014 and focuses on developing selective oral immunology therapies for treating chronic inflammatory and autoimmune diseases. Immunic operates as a research-focused organization with no current revenue-generating products, instead investing heavily in clinical trials to advance its pipeline of experimental treatments through various phases of regulatory approval.
Similar companies
Latest newsMore news →
IMMUNIC, INC. appointed Jaa Roberson as its first Chief People Officer, reporting to CEO Erik Lundgren and joining the executive leadership team.16h agoImmunic announced that four abstracts on clinical, biomarker and preclinical data for investigational vidofludimus calcium were accepted for presentation at MSToronto2026.13d ago